- |||||||||| prednisolone / Generic mfg.
Journal, Causal relationship: Trauma-induced myasthenia gravis: coincidence or causal relationship? (Pubmed Central) - Apr 30, 2021
In this report, we describe the timing and progression of MG in our patient, and review the literature pertaining to the relationship between trauma and MG. The search for definitive evidence of causation may be impractical, but should not delay the recognition and management of a treatable condition.
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion date, FDG PET, Metastases: RATHL: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov) - Apr 28, 2021
P3, N=1202, Active, not recruiting,
One-week treatment with daily 10 mg oral prednisolone was not effective on the patients with refractory LSS in the short-term follow-up. Trial completion date: Jan 2021 --> Jan 2022
- |||||||||| Revlimid (lenalidomide) / BMS
Clinical, P3 data, Journal, HEOR: Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. (Pubmed Central) - Apr 28, 2021
Side effect profile of treatment did not negatively affect global quality of life, but it was, however, clinically relevant for the patients. (Clinicaltrials.gov identifier: NTR1630).
- |||||||||| prednisolone / Generic mfg.
Clinical, Journal: Predictors of patient adherence to COPD self-management exacerbation action plans. (Pubmed Central) - Apr 28, 2021
HDAC-2 levels at baseline might be a good biomarker for predicting steroid response in patients with DMD. Tailored self-management support with more focus on dyspnoea and cardiac disease symptoms may help patients to better act upon increased exacerbation symptoms and improve adherence to COPD exacerbation action plans.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Clinical, Journal: Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease. (Pubmed Central) - Apr 28, 2021
Although anti-interleukin-6 therapy with tocilizumab and siltuximab is recommended for multicentric Castleman's disease (MCD), burdens caused by frequent hospital visits and high drug payments is an issue to be considered...Therefore, we conducted a retrospective analysis of Castleman's disease patients to explore predictors of glucocorticoid responsiveness and revealed that higher hemoglobin and/or lower C-reactive protein levels before starting glucocorticoid monotherapy were associated with lower probability of requirements for second-line treatment among patients initially treated with glucocorticoid. We concluded that glucocorticoids had a potential to induce sustained disease control for indolent MCD patients with specific clinical characteristics.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: Crescentic glomerulonephritis in children. (Pubmed Central) - Apr 27, 2021
The treatment success of cGN is dependent on early diagnosis and aggressive therapy, as well as on the percentage of crescentic glomeruli on renal biopsy and on the underlying type of cGN. CsA and MMF seem to be effective alternatives to cyclophosphamide.
- |||||||||| prednisolone / Generic mfg.
Clinical, Journal: Sarcoidosis with marked necrosis in enlarged lymph nodes mimics mycobacterial infection: a case report. (Pubmed Central) - Apr 27, 2021
Sarcoidosis must be considered even if pathological findings reveal marked necrosis, because rare cases of sarcoidosis exhibit extensive necrosis in lymph nodes. It is extremely important to carefully examine the clinical and pathological findings through discussion with the examining pathologist to reach the correct diagnosis.
- |||||||||| prednisolone / Generic mfg.
Journal: Prednisolone Alters Endometrial Decidual Cells and Affects Decidual-Trophoblast Interactions. (Pubmed Central) - Apr 27, 2021
Conditioned media from hESF decidualized in the presence of prednisolone significantly enhanced trophoblast outgrowth and trophoblast mRNA expression of cell motility gene PLCG1 and reduced trophoblast production of PGF. Prednisolone treatment during the menstrual cycle and 1st trimester of pregnancy might alter decidual interactions with other cells, including invasive trophoblast.
- |||||||||| prednisolone / Generic mfg.
[VIRTUAL] Chronic Granulomatous Disease with Associated IgG4-Related Disease Masquerading as Pulmonary Pseudotumor () - Apr 23, 2021 - Abstract #CIS2021CIS_183;
Treatment with prednisolone resulted in considerable symptom resolution...He was eventually diagnosed with concurrent CGD and IgG4RD, but progressed to respiratory failure and died despite the reinstitution of steroid therapy. Further studies to investigate IgG subsets among IEI patients with pulmonary manifestations can help elucidate clinicopathological correlations between IgG4RD and IEIs.
- |||||||||| sirolimus / Generic mfg.
[VIRTUAL] Multicentric Castleman Disease revealing STAT1 deficiency () - Apr 23, 2021 - Abstract #CIS2021CIS_115;
Modification of therapy allowed to maintain a sustainable remission of the disease and a complete withdrawal of steroids. While in complete remission, our patient underwent hematopoietic stem cell transplantation with a match unrelated donor.
- |||||||||| verapamil / Generic mfg., sirolimus / Generic mfg., carbamazepine / Generic mfg.
Journal: Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms. (Pubmed Central) - Apr 23, 2021
In order to propose potential candidate drugs for the selected biomarkers, we designed filters considering toxicity and regulation ability. With the proposed systematic procedure, we not only shed a light on the differences between carcinogenetic molecular mechanisms of TNBC and non-TNBC but also efficiently proposed candidate multi-molecule drugs including resveratrol, sirolimus, and prednisolone for TNBC and resveratrol, sirolimus, carbamazepine, and verapamil for non-TNBC.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Disease-modifying treatments for primary autoimmune haemolytic anaemia. (Pubmed Central) - Apr 22, 2021
Available literature on the effectiveness of immunomodulatory therapy for primary AIHA is restricted to comparison between rituximab plus glucocorticoid and glucocorticoid alone, in patients with newly diagnosed warm AIHA, calling for need for additional studies. The current result suggests that combinatory therapy with rituximab and glucocorticoid may increase the rate of complete haematological response over glucocorticoid monotherapy.
- |||||||||| prednisolone / Generic mfg.
Journal: Seven Common Allergen Groups Causing Eyelid Dermatitis: Education and Avoidance Strategies. (Pubmed Central) - Apr 22, 2021
Of the corticosteroids, only tixocortol pivalate (the screening agent for prednisolone and fluorometholone) and budesonide elicited positive reactions...Avoidance of these allergens can be straightforward, with initial empiric counseling and free, online allergen avoidance programs. Patients who are unresponsive to avoidance should undergo patch testing.
- |||||||||| lomustine / Generic mfg., prednisolone / Generic mfg.
Journal: Lymphoid leukemia in five bearded dragons (Pogona vitticeps). (Pubmed Central) - Apr 20, 2021
For infantile spasm resolution 2 weeks after treatment initiation, current evidence does not support the preeminence of ACTH in terms of effectiveness and, especially, cost-effectiveness. The present report represented the first description of lomustine as a primary chemotherapeutic agent for the treatment of lymphocytic leukemia in bearded dragons and provided information on response to treatment, adverse effects, and survival times.
- |||||||||| Simulect (basiliximab) / Novartis
[VIRTUAL] DOES EARLY ASYMPTOMATIC BACTERIURIA AFFECT GRAFT OUTCOMES IN KIDNEY TRANSPLANT RECIPIENTS FROM SOUTH ASIA? () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1340;
The primary immunosuppression was Prednisolone, tacrolimus and mycophenolate mofetil in 750 patients (94.5%)...Conclusions ASB and UTI are common in the first 3 months post kidney transplant with half of early ASB episodes being treated. Treatment of early post-transplant ASB (First ASB <3months) had no impact on patient or graft survival when compared to untreated ASB.
- |||||||||| prednisolone / Generic mfg., azathioprine / Generic mfg.
[VIRTUAL] LONG TERM BENEFITS OF PRESERVED GRAFT FUNCTIONS AFTER LATE WITHDRAWAL OF CALCINEURIN INHIBITORS IN LIVE DONOR KIDNEY TRANSPLANT RECIPIENTS. () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1324;
Conclusions Recipients of kidney from live donors with at least 1 haplo match and who did not have rejections in the1st year of transplant had excellent long term graft survival with 2 drugs only without CNI.In selected live donor transplant recipients who do not have rejection in first year calceinurin inhibitors can safely be withdrawn at least one year after transplant which helps in ameliorating CNI induced renal injury and prevents further deterioration of renal functions. In patients with graft dysfunction with histological features of CNI toxicity this beneficial effect of CNI withdrawal can sometimes be seen even many years after transplantation.
- |||||||||| Simulect (basiliximab) / Novartis, Cytovene (ganciclovir) / Roche
[VIRTUAL] SUSTAINED BK VIRURIA: A FORGOTTEN ALLY FOR EARLY DIAGNOSIS OF BK VIRUS NEPHROPATHY IN KIDNEY TRANSPLANTATION () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1287;
Immunosuppression (IS) consisted of Basiliximab, Tacrolimus (TAC), Mycophenolate Mofetil (MMF) and Prednisolone (PDN)...19,3 months after KT he had CMV infection treated with Ganciclovir and suspension of MMF...IS was changed to everolimus (EVR) and low dose TAC...Our study highlights the importance of BK viruria screening, and that BKVN should be considered in KT patients with allograft disfunction and persistent viruria, even without viremia. The early recognition of BK viruria could guide early therapeutic decisions with impact on the outcome of BKVN.
- |||||||||| hydroxychloroquine / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] RENAL TRANSOLANTATION STRUGGLES DURING COVID-19 ERA: DRUG/DRUG INTERACTION MAY LEAD TO GRAFT LOSS () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1265;
Creatinine level baseline 81-91 µmol/L remained stable Tacrolimus was not reintroduced during hospitalization. Conclusions Recommendations for renal transplant patients with Covid-19 infection involved supportive measures without initiation of antiviral therapy inform of favipiravir and lopinavir/ritonavir due to sever drug/drug interactions which could cause CNI toxicity and graft loss as noted.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
[VIRTUAL] Euglycemic Diabetic Ketoacidosis Related to SGLT2 Inhibitor Use in Kidney Transplant Patient with Squamous Cell Carcinoma () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1263;
Her home medications included insulin glargine, dapagliflozin 10 mg, pantoprazole 40mg, prednisolone 7.5 mg daily, cyclosporine 125 mg q12 hours and atorvastatin 20mg...She was initiated on concurrent chemotherapy (Cetuximab) and radiotherapy...She required critical care admission with rigorous IV hydration, insulin infusion per DKA protocol, IV sodium bicarbonate, IV hydrocortisone and IV cyclosporine...Conclusions SGLT2 inhibitor associated eDKA is very rare in oncology patients and this is the first case reported in kidney transplant patient who was on active chemotherapy and radiotherapy for squamous cell carcinoma. We suggest to hold SGLT2i therapy during active oncology treatment especially in the setting on severe mucositis.
- |||||||||| sirolimus / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] Outcomes of Malignancy in Kidney Transplant Recipients () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1261;
Conclusions the incidence of cancer in our KT recipients over 10 years was 4.9 % with predominance of late onset hematological malignancies mainly lymphoma. Larger studies are needed to elucidate the potential risk factors for malignancy in KT and understand the geographical difference in types of cancers in such patients.
- |||||||||| prednisolone / Generic mfg.
[VIRTUAL] PROGNOSIS OF IGA PATIENT AFTER THREE CONSEQUENT REMISSION IN PROTEINURIA AND HEMATURIA OVER SIX MONTHS OF FOLLOW-UP () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1099;
Methods This was a retrospective study included 75 IgAN patients diagnosed and treated with methyl-prednisolone pulse therapy between 2003 and 2014 in Nagoya University Hospital...Conclusions Proteinuria remission indicates a favorable renal outcome in IgAN patients, but relapses are common and, in a small percentage poor renal outcomes occurred. Therefore our data suggest that even relapses cases should be monitored on a regular basis.
- |||||||||| prednisolone / Generic mfg.
[VIRTUAL] GRANULOMATOUS INTERTITIAL NEPHRITIS : A SERIE OF FIVE PATIENTS () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1047;
Corticosteroid therapy using prednisolone 1 mg/kg per day was used in all patients...Histologic features do not seem to distinguish the underlying cause of GIN. Corticosteroids therapy seems to be efficient and must be introduced early to prevent progression to chronic renal failure and it is associated with a good prognosis.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] EFFICACY AND SAFETY OF RITUXIMAB VERSUS TACROLIMUS IN FREQUENTLY RELAPSING NEPHROTIC SYNDROME: AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_1029;
Methods This single-center open-label randomized clinical trial (RCT) examined the non-inferiority of rituximab (2 doses at 375 mg/m2 one week apart) as compared to oral tacrolimus (0.1-0.2 mg/kg in two divided doses for one year) in patients, 1-18 years-old with difficult-to-treat steroid sensitive nephrotic syndrome (failure of ≥2 therapies)...Both groups showed considerable and comparable reduction in relapse rates and prednisolone usage (85% and 70%, respectively)...Conclusions In children with frequently relapsing nephrotic syndrome failing multiple steroid-sparing therapies, rituximab was not non-inferior to tacrolimus in maintaining sustained remission. Compared to tacrolimus, rituximab was associated with increased risk of frequent relapses.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] IMMUNE CHECKPOINTS INHIBITORS-ASSOCIATED ACUTE KIDNEY INJURY: A SINGLE-CENTRE STUDY () - Apr 17, 2021 - Abstract #ISNWCN2021ISN-WCN_781;
Methods The data of all patients receiving either avelumab, durvalumab, pembrolizumab, nivolumab, ipilimumab or atezolizumab between December 2011 and November 2020 were collected retrospectively using electronic patient records...The median time to steroid tapering to 10 prednisolone-equivalent mg/day was 46 (IQR 30-81) days...In the majority of patients, ICPi-AKI led to a change in anti-cancer therapy. We suggest that more awareness is necessary and that diagnostic investigations should be included in screening tests during ICPi administration and during AKI assessment.
|
